The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Helios Kliniken GmbH
Stock and Other Ownership Interests - Fresenius; GlaxoSmithKline
 
Honoraria - Amgen; AstraZeneca; Celgene; Clovis Oncology; CureVac; Eisai; Genomic Health; Immunomedics (Inst); Janssen-Cilag; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche/Genentech; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Celgene; CureVac; Eisai; Genomic Health; Immunomedics (Inst); Janssen-Cilag; Novartis; Pfizer; Roche (Inst); Tesaro; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche
NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.
 
Elena Ioana Braicu
Honoraria - AstraZeneca; Covis Pharma; GlaxoSmithKline; MSD; Roche Pharma AG; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; ImmunoGen; MSD; Roche Pharma AG; Takeda; Tesaro
Research Funding - Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD; Roche Pharma AG
 
Pauline Wimberger
Consulting or Advisory Role - Amgen; AstraZeneca; MSD; Novartis; Roche Pharma AG; Tesaro
Research Funding - Amgen; Novartis
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche Pharma AG
 
Rolf Richter
No Relationships to Disclose
 
Maren Keller
No Relationships to Disclose
 
Petra Krabisch
No Relationships to Disclose
 
Mustafa Deryal
Consulting or Advisory Role - PharmaMar
Travel, Accommodations, Expenses - PharmaMar
Other Relationship - PharmaMar
 
Ingo B. Runnebaum
Honoraria - Clovis Oncology
Consulting or Advisory Role - Caresyntax; oncgnostics; Tesaro
Research Funding - PharmaMar
 
Ralf Witteler
Honoraria - AstraZeneca
Consulting or Advisory Role - Roche Pharma AG; Tesaro
Research Funding - AstraZeneca; MSD; Roche Pharma AG; Tesaro
Travel, Accommodations, Expenses - Tesaro
 
Nikola Bangemann
No Relationships to Disclose
 
Frederik Marmé
No Relationships to Disclose
 
Michael Eichbaum
No Relationships to Disclose
 
Florian Heitz
Honoraria - AstraZeneca; Clovis Oncology; Roche Pharma AG; Tesaro
Consulting or Advisory Role - Clovis Oncology
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; PharmaMar; Tesaro
 
Barbara Schmalfeldt
Honoraria - AstraZeneca; Clovis Oncology; Ethicon; Roche Pharma AG; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Ethicon; Novartis; Roche Pharma AG; Tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ethicon; MSD; PharmaMar; Roche Pharma AG
 
Eva Egger
No Relationships to Disclose
 
Dorothea Fischer
Honoraria - Eisai; Novartis; Pfizer; Roche Pharma AG
 
Radoslav Chekerov
No Relationships to Disclose
 
Jacek P. Grabowski
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; Pfizer; RIEMSER; Roche Pharma AG; Vifor Pharma
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; Pfizer; RIEMSER; Roche Pharma AG; Vifor Pharma
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Tesaro (Inst); Institut Allergosan (Inst); MSD (Inst); RIEMSER (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; Pfizer; RIEMSER; Roche Pharma AG
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novocure; Pfizer; PharmaMar; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro